肾素抑制剂阿利吉仑  

Direct renin inhibition:Aliskiren

作　　者：张雅娉[1] 袁洪[1] 黄志军[1] 

机构地区：[1]中南大学湘雅三医院心内科,长沙450013

出　　处：《中国临床药理学杂志》2012年第3期221-224,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家"重大新药创制"科技重大专项子项目基金资助项目(2009ZX09501-032)

摘　　要：阿利吉仑(aliskiren)用于肾素-血管紧张素-醛固酮系统(RAAS)的起始步骤达到降压目的,其半衰期极长,耐受性可与安慰剂相媲美。单用阿利吉仑的降压疗效与其他一线降压药相似,甚至更优;联合用药疗效明显提高,不发生有害的药物间相互作用。对于特殊高血压人群如合并糖尿病、肥胖、或是老年高血压病人,阿利吉仑也表现出极好的疗效和耐受性。阿利吉仑对靶器官起到明显的保护作用,可逆转和延缓高血压引起的心血管和肾脏损害。Aliskiren is an effective antihypertensive drug by inhibiting the renin-angiotensin system.It has a prolonged duration of action and favorable tolerability comparable with placebo.The blood pressure-lowering effect of aliskiren monotherapy is similar,if not superior,to that of other first-line antihypertensive agents,and is greatly enhanced when aliskiren is combined with various other antihypertensive medications,without any adverse drug interactions.Aliskiren is also an effective and well tolerated therapy in special populations,including diabetic,obese,and elderly hypertensives.Beyond its blood pressure-lowering efficacy,aliskiren has positive effects on markers of cardiovascular and renal damage.

关 键 词：肾素抑制剂 阿利吉仑 高血压 

分 类 号：R972.4[医药卫生—药品]